Archive · 7 Aug 2025
Lupin Q1: Strong Earnings Lead to Brokerage 'Buy' Rating
Lupin, a pharmaceutical company, had a good financial quarter.
Their earnings before interest, taxes, depreciation, and amortization (EBITDA) went up by 28% and sales increased.
The US market performed well.
The company made a profit, which was more than predicted.
Because of the positive results, a brokerage firm recommends buying the stock, expecting it to increase in value.
Lupin's Q1FY26 EBITDA reached ₹1,640 crore, a 28% increase year-over-year.
Revenues grew 12% year-over-year to ₹6,300 crore, slightly below estimates.
US revenues increased 15% quarter-over-quarter to $282 million.
Net Profit After Tax (PAT) was ₹1,220 crore, exceeding expectations.
Brokerage maintains a Buy rating with a target price of ₹2,400.
- Who
- Lupin (LPC).
- What
- Lupin's Q1FY26 financial results were strong, with increased EBITDA and revenue.
- When
- The financial results are for Q1FY26 (Quarter 1 of Fiscal Year 2026).
- Where
- The company operates with a strong presence in the US market.
- Why
- Driven by better product mix, niche launches in the US, and cost optimization.
- EBITDA (Q1FY26)
- ₹1,640 crore
- Revenue (Q1FY26)
- ₹6,300 crore
- US Revenue
- $282mn
- PAT
- ₹1,220 crore
- Gross Margins
- 71.3%
- R&D Expenses
- ₹470 crore
- Broker Rating
- Buy
- Target Price
- ₹2,400
